IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Jian He 1* , Jian Wu 1* , Yuchen Jiao 1 , Nina Wagner-Johnston 2 , Richard F. Ambinder 3 , Luis A Diaz Jr 1 , Kenneth W Kinzler 1 , Bert Vogelstein 1 , and Nickolas Papadopoulos 1 1 The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 2 Washington University School of Medicine, St. Luis, MO 3 The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD * J.H. and J.W. contributed equally to this work Keywords: Cancer, leukemia, lymphoma, biomarkers, gene rearrangements Received: March 6, 2011; Accepted: March 7, 2011; Published: March 8, 2011; Correspondence: Bert Vogelstein, e-mail: // // Abstract New biomarkers with improved accuracy could be helpful for monitoring disease in patients with Non-Hodgkin's lymphomas (NHL). Towards this end, we have explored the feasibility of identifying the sequence of rearranged IgH genes using next-generation sequencing, then using PCR to detect specific rearranged DNA fragments in patients’ plasma. By capturing and sequencing the IgH genomic regions (IgCap), we were able to detect and precisely determine the sequence of rearranged IgH loci in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments could be identified in the plasma of all three patients. Even in cases wherein tumor biopsies were unavailable, we were able to use the IgH capture approach to identify rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed management of selected patients with NHL and other B-cell malignancies in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Self-citationVogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770 · cited 1×
“Digital PCR was performed as described before.[22]”
Self-citationComprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J., Kahsai, O., Riddell, S. R., Warren, E. H., & Carlson, C. S. (2009) · Blood · doi:10.1182/blood-2009-04-217604 · Cited by 1,122
Circulating nucleic acids (CNAs) and cancer—A survey
Fleischhacker, M., & Schmidt, B. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.10.001 · Cited by 851
Emerging molecular markers of cancer
Sidransky, D. (2002) · Nature Reviews Cancer · doi:10.1038/nrc755 · Cited by 662 · cited 1×
“[2] Among the many new biomarkers being developed, those employing free, circulating somatically mutated DNA sequences in the plasma are particularly attractive because they can in theory meet all these criteria.[3, 4] In particular, mutations are exquisitely tumor-specific because they are not found in any collection…”
Background
Cited by
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Leary, R. J., Sausen, M., Kinde, I., Papadopoulos, N., Carpten, J. D., Craig, D., O’Shaughnessy, J., Kinzler, K. W., Parmigiani, G., Vogelstein, B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004742 · Cited by 635
Self-citationNoninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635169 · Cited by 337
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
“0 (Agilent), whereas the custom solid-phase capture assay was performed by modification of previously described methods (48, 49).”
MethodSelf-citation
Metadata
- Authors
- He, J., Wu, J., Jiao, Y., Wagner-Johnston, N., Ambinder, R. F., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2011-03-08
- Volume
- 2
- Issue
- 3
- Pages
- 178-185
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2108902335
- Cited by
- 66
- References
- 5
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.